Brief: Exelixis Announces Positive Results From Phase 3 Cabinet Pivotal Trial

Exelixis

24/08/2023 13:03

Aug 24 (Reuters) - Exelixis Inc  EXEL.O :
    * EXELIXIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 CABINET
PIVOTAL
TRIAL EVALUATING CABOZANTINIB IN ADVANCED PANCREATIC AND
EXTRA-PANCREATIC NEUROENDOCRINE TUMORS
    * EXELIXIS INC -SAFETY PROFILE OF CABOZANTINIB OBSERVED IN
TRIAL
WAS CONSISTENT WITH ITS KNOWN SAFETY PROFILE, NO NEW SAFETY
SIGNALS WERE IDENTIFIED
    * EXELIXIS INC - BASED ON POSITIVE RESULTS, FINDINGS WILL BE
DISCUSSED WITH U.S. FOOD AND DRUG ADMINISTRATION
    * EXELIXIS INC - CABINET TRIAL WILL BE UNBLINDED AND STOPPED
EARLY
DUE TO A DRAMATIC IMPROVEMENT IN EFFICACY

Source text for Eikon:  ID:nBwSJwlRa 
Further company coverage:  EXEL.O 

 (Reuters.Briefs@thomsonreuters.com)